Expertise in
8
conditions

Dr. Craig M. Zaidman

Neurology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral required
Before you request
Expertise in
8
conditions
Washington University
660 S Euclid Ave, 
Saint Louis, MO 

Overview

Craig Zaidman is a Neurologist practicing medicine in Saint Louis, Missouri.

Dr. Zaidman is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis.

He is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 8 clinical trials. Dr. Zaidman is currently accepting new patients.

Specialties

Neurology

Licenses

Neurology with Special Qualifications in Neurology in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
View 7 Less Clinical Trials

83 Total Publications

Biallelic SCO2 Variants Presenting as Motor-Predominant Axonal Neuropathy With Complex IV Deficiency.
Biallelic SCO2 Variants Presenting as Motor-Predominant Axonal Neuropathy With Complex IV Deficiency.
Journal: Journal of the peripheral nervous system : JPNS
Published: May 13, 2026
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.1 miles away)
314-454-6120
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Gutmann is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Gutmann is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Optic Glioma, Neurofibromatosis Type 1 (NF1), and Glioma. Dr. Gutmann is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

St. Louis Children's Hospital

1 Childrens Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-454-6120
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Renee Shellhaas is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Shellhaas is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Epilepsy in Children, West Syndrome, Spasmus Nutans, and Seizures. Dr. Shellhaas is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-747-1171
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Milan Chheda is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Chheda is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Chheda is currently accepting new patients.

Frequently Asked Questions about Dr. Craig M. Zaidman

How do I make an appointment with Dr. Craig M. Zaidman?

You can book an appointment with Dr. Craig M. Zaidman by calling their office at 314-362-6981. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig M. Zaidman a top-rated expert for Becker Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig M. Zaidman is classified as an Elite expert for Becker Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig M. Zaidman specialize in?

While Dr. Craig M. Zaidman is a Neurology, they have specific expertise in Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Spinal Muscular Atrophy (SMA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Craig M. Zaidman participate in research or clinical trials?

Yes. Dr. Craig M. Zaidman has published 83 articles and abstracts on conditions like Becker Muscular Dystrophy. You can view a list of Dr. Craig M. Zaidman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig M. Zaidman accept my insurance?

Dr. Craig M. Zaidman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-362-6981 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zaidman's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile